Michael Mithoefer
Biographic Data
| ID | 5525272 |
|---|---|
| NAME | Michael Mithoefer |
| GIVEN NAMES | Michael |
| FAMILY NAME | Mithoefer |
| SIGNATURE | MITHOEFER M |
| AFFILIATIONS | MAPS Public Benefit Corporation (MAPS PBC), San Jose, CA, USA |
| VERIFIED | No |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 1 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 1 |
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder
https://clinicaltrials.gov/ct2/show/NCT02102802, identifier NCT02102802
Group psychedelic therapy
Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies. By enhancing the number of patients served per clinician, group therapy could also ameliorate the anticipated shortage of appropriately trained clinicians, thereby accelerating access to these promising new therapies
MDMA-assisted therapy for severe PTSD
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities suc…
Scaling Up
Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized therapy across 14 North American sites. Method: Cotherap…
Scaling Up
Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized therapy across 14 North American sites. Method: Cotherap…
MDMA-assisted therapy for severe PTSD
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities suc…
Scaling Up
Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized therapy across 14 North American sites. Method: Cotherap…
Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder
https://clinicaltrials.gov/ct2/show/NCT02102802, identifier NCT02102802
Group psychedelic therapy
Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies. By enhancing the number of patients served per clinician, group therapy could also ameliorate the anticipated shortage of appropriately trained clinicians, thereby accelerating access to these promising new therapies
MDMA (4 works) · Medicine (4 works) · Psychedelics and Drug Studies (4 works) · Psychiatry (4 works) · Psychology (3 works) · Adverse effect (2 works) · Cannabis and Cannabinoid Research (2 works) · Internal Medicine (2 works) · Amygdala (1 work) · Anxiety (1 work)